Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report

Background Abacavir is a nucleoside reverse transcriptase inhibitor that is used as a component of the antiretroviral treatment regimen in the management of the human immunodeficiency virus for both adults and children.

It is efficacious, but its use may be limited by a hypersensitivity reaction linked with the HLA-B *57:01 genotype.

HLA-B *57:01 has been reported to be rare in African populations.

Because of the nature of its presentation, abacavir hypersensitivity is prone to late diagnosis and treatment, especially in settings where HLA-B *57:01 genotyping is not routinely done.

Case report We report a case of a severe hypersensitivity reaction in a 44-year-old Kenyan female living with the human immunodeficiency virus and on abacavir-containing antiretroviral therapy.

The patient presented to the hospital after recurrent treatment for a throat infection with complaints of fever, headache, throat ache, vomiting, and a generalized rash.

Laboratory results evidenced raised aminotransferases, for which she was advised to stop the antiretrovirals that she had recently been started on.

The regimen consisted of abacavir, lamivudine, and dolutegravir.

She responded well to treatment but was readmitted a day after discharge with vomiting, severe abdominal pains, diarrhea, and hypotension.

Her symptoms disappeared upon admission, but she was readmitted again a few hours after discharge in a hysterical state with burning chest pain and chills.

Suspecting abacavir hypersensitivity, upon interrogation she reported that she had taken the abacavir-containing antiretrovirals shortly before she was taken ill.

A sample for HLA-B *57:01 was taken and tested positive.

Her antiretroviral regimen was substituted to tenofovir, lamivudine, and dolutegravir, and on subsequent follow-up she has been well.

Conclusions Clinicians should always be cognizant of this adverse reaction whenever they initiate an abacavir-containing therapy.

We would recommend that studies be done in our setting to verify the prevalence of HLA-B *57:01.